Month: November 2022

Yuan, Jiwen; Ma, Xu; Yi, Hong; Liu, Chao; Lei, Aiwen published an article in 2014, the title of the article was I2-catalyzed oxidative C(sp3)-H/S-H coupling: utilizing alkanes and mercaptans as the nucleophiles.Quality Control of Benzyl(4-bromophenyl)sulfane And the article contains the following content:

By using alkanes and mercaptans as the nucleophiles with di-tert-Bu peroxide (DTBP) as the oxidant, I2-catalyzed oxidative C(sp3)-H/S-H coupling was achieved. This protocol provides a novel process to construct C(sp3)-S bonds from com. available hydrocarbons and mercaptans. The experimental process involved the reaction of Benzyl(4-bromophenyl)sulfane(cas: 53136-21-3).Quality Control of Benzyl(4-bromophenyl)sulfane

The Article related to alkane mercaptan oxidative coupling, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Alcohols and Thiols and other aspects.Quality Control of Benzyl(4-bromophenyl)sulfane

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On February 19, 2013, Chen, Wei; Loury, David J. published a patent.COA of Formula: C14H21BO3 The title of the patent was Preparation of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives as Btk kinase inhibitors. And the patent contained the following:

The invention related to pyrazolo[3,4-d]pyrimidine derivatives of formula I, pharmaceutical composition comprising them, their preparations and use as Bruton’s tyrosine kinase (Btk) inhibitors thereof. Compounds of formula I wherein X is a bond; Y is (un)substituted (hetero)arylene; Z is CO, CS, S(O)1-2, NHCO and derivatives, and NHSO1-2 and derivatives; R1 and R2 are independently H, (un)substituted (hetero)aryl, heterocycloalkyl, C1-4 alkyl and C3-6 cycloalkyl; or R1R2 taken together form a heterocycloalkyl ring; each R3 is independently halo, C1-4 alkyl, CF3, CN, NO2, NH2, OH and OMe; m is 1 – 3; and their pharmaceutically acceptable salt, are claimed. Example compound II was prepared by amination of (R)-tert-Bu 3-hydroxy-1-pyrrolidinecarboxylate with 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine,the resulting substituted pyrazolopyrimidine underwent deprotection followed by N-acylation with 4-(dimethylamino)but-2-enoic acid to afford 2-(E)-1-((R)-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-4-(dimethylamino)but-2-en-1-one, which underwent coupling reaction with 4-chlorophenylboronic acid to afford compound II. All the invention compounds were evaluated for their Btk inhibitory activity. From the assay, it was determined that example compound II exhibited IC50 value of < 100 nM. The experimental process involved the reaction of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(cas: 1417036-28-2).COA of Formula: C14H21BO3

The Article related to pyrazolopyrimidine preparation btk kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.COA of Formula: C14H21BO3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On July 4, 2013, Chen, Wei; Loury, David J. published a patent.Computed Properties of 1417036-28-2 The title of the patent was Preparation of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine derivatives as Btk kinase inhibitors. And the patent contained the following:

The invention related to pyrazolo[3,4-d]pyrimidine derivatives of formula I and their pharmaceutically acceptable salts as Bruton’s tyrosine kinase (Btk) inhibitors; pharmaceutical composition comprising them and their preparations and use thereof. Compounds of formula I wherein A is CH and N; Y is (un)substituted (hetero)arylene, cycloalkylene, heteroalkylene, etc; Z is CO, NHCO, NHSO1-2, etc.; R6, R7 and R8 are independently H and L-J-W; L and J are independently a bond, (un)substituted C1-6 alkylene, (un)substituted C3-6 cycloalkylene, etc.; W is H, NH2 and derivatives; R2 is H, CN, NO2, etc.; R4 is independently H, CN, NO2, etc.; and their pharmaceutically acceptable salt, are claimed. Example compound II was prepared by amination of (R)-tert-Bu 3-hydroxy-1-pyrrolidinecarboxylate with 3-iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine,the resulting substituted pyrazolopyrimidine underwent deprotection followed by N-acylation with 4-(dimethylamino)but-2-enoic acid to afford 2-(E)-1-[(R)-(4-amino-3-iodo-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl]-4-(dimethylamino)but-2-en-1-one, which underwent coupling reaction with 4-chlorophenylboronic acid to afford compound II. The invention compounds were evaluated for their Btk inhibitory activity. From the assay, it was determined that example compound II exhibited IC50 value of < 100 nM. The experimental process involved the reaction of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(cas: 1417036-28-2).Computed Properties of 1417036-28-2

The Article related to pyrazolopyrimidine preparation btk kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Computed Properties of 1417036-28-2

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On November 11, 2009, Liu, Weidong; Nichols, Paul J.; Smith, Nathan published an article.Quality Control of 2-(2-(Vinyloxy)ethoxy)ethanol The title of the article was Di(ethylene glycol) vinyl ether: a highly efficient deactivating reagent for olefin metathesis catalysts. And the article contained the following:

A highly efficient method for deactivating commonly used olefin metathesis catalysts is described. Inexpensive and com. available di(ethylene glycol) vinyl ether is found to quench both first- and second-generation Grubbs’ carbenes in less than 10 min at room temperature The resulting ruthenium byproducts are readily removed by silica gel purification The experimental process involved the reaction of 2-(2-(Vinyloxy)ethoxy)ethanol(cas: 929-37-3).Quality Control of 2-(2-(Vinyloxy)ethoxy)ethanol

The Article related to diethylene glycol vinyl ether deactivation olefin metathesis catalyst, Aliphatic Compounds: Esters, Linear Anhydrides, Acyl Peroxides, and Acyl Halides and other aspects.Quality Control of 2-(2-(Vinyloxy)ethoxy)ethanol

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On August 6, 2021, Dao, Pham Duy Quang; Cho, Chan Sik published an article.SDS of cas: 93-04-9 The title of the article was Synthesis of Trinuclear Benzimidazole-Fused Hybrid Scaffolds by Transition Metal-Free Tandem C(sp2)-N Bond Formation under Microwave Irradiation. And the article contained the following:

The compounds 2-(2-bromoaryl)benzimidazoles e.g., 2-(2-bromocyclohex-1-en-1-yl)-1H-1,3-benzodiazole and 2-(2-bromovinyl)benzimidazoles e.g., 2-[(1Z)-1-bromo-1-phenylprop-1-en-2-yl]-1H-1,3-benzodiazole have been coupled and cyclized with 2-methoxybenzimidazoles e.g., 2-methoxy-1H-1,3-benzodiazole and 2-aryloxybenzimidazoles e.g., 2-methoxy-1H-naphtho[2,3-d]imidazole as building blocks in the presence of a base under microwave irradiation to give a class of trinuclear N-fused hybrid scaffolds, benzo[4,5]imidazo[1,2-a]benzo[4,5]imidazo[1,2-c]quinazolines e.g., I and benzo[4,5]imidazo[1,2-a]benzo[4,5]imidazo[1,2-c]pyrimidines e.g., II, resp., in good yields. The compounds 2-(2-bromoaryl)imidazoles e.g., 2-(2-bromocyclohex-1-en-1-yl)-4,5-diphenyl-1H-imidazole and 2-(2-bromovinyl)imidazoles e.g., (Z)-2-(1-bromo-1-phenylprop-1-en-2-yl)-4,5-diphenyl-1H-imidazole also reacted with 2-methoxybenzimidazoles (e.g., 2-methoxy-1H-1,3-benzodiazole/e.g., 2-methoxy-1H-naphtho[2,3-d]imidazole) in the presence of base under microwave irradiation to give a class of trinuclear N-fused hybrid scaffolds, benzo[4,5]imidazo[1,2-a]imidazo[1,2-c]quinazolines e.g., III and benzo[4,5]imidazo[1,2-a]imidazo[1,2-c]pyrimidines e.g., IV, resp., in similar yields. This process seems to proceed via an initial C(sp2)-N coupling by an addition-elimination nucleophilic aromatic substitution (SNAr) and subsequent cyclization accompanied by extrusion of alcs. The experimental process involved the reaction of 2-Methoxynaphthalene(cas: 93-04-9).SDS of cas: 93-04-9

The Article related to trinuclear fused heterocyclic compound preparation microwave green chem, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 93-04-9

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On November 1, 2012, Tsuhako, Amy Lew; Marlowe, Charles K.; Zaharia, Christiana A.; Kabigting, Lori; Bajjalieh, William; Tesfai, Zerom; Huang, Ping; Moon, Kim; Aay, Naing; Tambo-Ong, Arlyn; Nuss, John M.; Xu, Wei; Kearney, Patrick published a patent.Safety of (2-Bromo-5-methoxyphenyl)methanamine The title of the patent was Pyrimidine derivatives as inhibitors of inducible form of 6-phosphofructose-2-kinase and their preparation and use for the treatment of cancer. And the patent contained the following:

The invention relates to pyrimidines of formula I, which are inhibitors of inducible form of 6-phosphofructose-2-kinase (iPFK-2) and which are useful in the treatment of cancer. Compounds of formula I wherein W is (un)substituted (un)branched C1-12 aliphatic chain; X1, X2 and X3 are independently absent, (un)substituted aryl, (un)substituted heteroaryl, etc.; Y is absent and (un)substituted (un)branched C1-12 aliphatic chain; Z is H, (un)substituted C1-8 aliphatic, (un)substituted aryl, etc.; L is absent, NH and derivatives and (un)substituted (un)branched C1-4 aliphatic chain; A is (un)substituted aryl, (un)substituted heteroaryl, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their iPFK-2 inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of <500 nM. The experimental process involved the reaction of (2-Bromo-5-methoxyphenyl)methanamine(cas: 887581-09-1).Safety of (2-Bromo-5-methoxyphenyl)methanamine

The Article related to pyrimidine preparation phosphofructose kinase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Safety of (2-Bromo-5-methoxyphenyl)methanamine

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On November 1, 2012, Tsuhako, Amy Lew; Marlowe, Charles K.; Zaharia, Christiana A.; Kabigting, Lori; Bajjalieh, William; Tesfai, Zerom; Huang, Ping; Moon, Kim; Aay, Naing; Tambo-Ong, Arlyn; Nuss, John M.; Xu, Wei; Kearney, Patrick published a patent.Application In Synthesis of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane The title of the patent was Pyrimidine derivatives as inhibitors of inducible form of 6-phosphofructose-2-kinase and their preparation and use for the treatment of cancer. And the patent contained the following:

The invention relates to pyrimidines of formula I, which are inhibitors of inducible form of 6-phosphofructose-2-kinase (iPFK-2) and which are useful in the treatment of cancer. Compounds of formula I wherein W is (un)substituted (un)branched C1-12 aliphatic chain; X1, X2 and X3 are independently absent, (un)substituted aryl, (un)substituted heteroaryl, etc.; Y is absent and (un)substituted (un)branched C1-12 aliphatic chain; Z is H, (un)substituted C1-8 aliphatic, (un)substituted aryl, etc.; L is absent, NH and derivatives and (un)substituted (un)branched C1-4 aliphatic chain; A is (un)substituted aryl, (un)substituted heteroaryl, etc.; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their iPFK-2 inhibitory activity. From the assay, it was determined that compound II exhibited an IC50 value of <500 nM. The experimental process involved the reaction of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(cas: 1417036-28-2).Application In Synthesis of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

The Article related to pyrimidine preparation phosphofructose kinase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Application In Synthesis of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On November 29, 2002, Coulon, Estelle; Pinson, Jean; Bourzat, Jean-Dominique; Commercon, Alain; Pulicani, Jean-Pierre published an article.Application of 53136-21-3 The title of the article was Surface-Modified Carbon Felts: Possible Supports for Combinatorial Chemistry. And the article contained the following:

It is possible to prepare carbon-based analogs of the Merrifield resin by electrochem. reduction of diazonium salts or oxidation of aryl acetates on high sp. surface area carbon felts. These modified felts can undergo further reactions: nucleophilic substitution, Suzuki reaction, and finally reductive electrochem. cleavage, taking advantage of the conductivity of the carbon felt. This provides a simple example of the possible use of electrochem. in combinatorial synthesis. The experimental process involved the reaction of Benzyl(4-bromophenyl)sulfane(cas: 53136-21-3).Application of 53136-21-3

The Article related to carbon felt support aryl sulfide electrochem reduction, aryl thiol preparation, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Alcohols and Thiols and other aspects.Application of 53136-21-3

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On October 18, 2018, Trzoss, Lynnie; Betancort, Juan Manuel; Kanouni, Toufike; Wallace, Michael Brennan; Boloor, Amogh published a patent.Recommanded Product: 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane The title of the patent was Preparation of N-containing heteroaryl pyridone compounds as selective CREB-binding protein inhibitors for treatment of cancer, immune disorders, and inflammatory diseases. And the patent contained the following:

The present embodiments relate to substituted heterocyclic derivatives of formula I, compositions comprising said compounds, and the use of said compounds and compositions for epigenetic regulation by inhibition of bromodomain-mediated recognition of acetyl lysine regions of proteins, such as histones. Compounds of I [wherein X = N or CR7; R7 = H, halo, alkyl, or alkoxy; R2 = H, alkyl, (hetero)aryl, etc.; R5 = H, halo, CN, (un)substituted aryl, etc.; R6 = H, halo, CN, heteroaryl, etc.; R8 = (un)substituted heteroaryl] or pharmaceutically acceptable salts thereof, are claimed and exemplified. Example compound II was prepared from a multistep procedure (preparation given). Said compositions and methods are useful for the treatment of diseases mediated by aberrant cell signaling, such as inflammatory disorders, cancer and neoplastic disease. Particular compounds described herein exhibit selective inhibitory activity against CREB-binding protein (CBP) compared with BRD4. Exemplified I were evaluated for CBP inhibitory activity with some compounds demonstrating IC50 values of ≥ 0.5 μM (data provided). The experimental process involved the reaction of 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane(cas: 1417036-28-2).Recommanded Product: 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

The Article related to heteroarylpyridone preparation creb binding protein cancer inflammation immune disorder, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Recommanded Product: 2-(3-Methoxy-4-methylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem

On November 19, 2010, Wang, Chen; Li, Shangfu; Liu, Hongxia; Jiang, Yuyang; Fu, Hua published an article.Category: ethers-buliding-blocks The title of the article was Copper-Catalyzed Synthesis of Quinazoline Derivatives via Ullmann-Type Coupling and Aerobic Oxidation. And the article contained the following:

A simple and efficient copper-catalyzed approach to quinazoline derivatives has been developed, and the protocol uses readily available substituted (2-bromophenyl)methylamines and amides as the starting materials, and the cascade reactions were performed under air via sequential Ullmann-type coupling and aerobic oxidation without addition of any ligand or additive. The present method provides a convenient and practical strategy for synthesis of quinazoline derivatives The experimental process involved the reaction of (2-Bromo-5-methoxyphenyl)methanamine(cas: 887581-09-1).Category: ethers-buliding-blocks

The Article related to quinazoline preparation, ullmann type coupling aerobic oxidation bromophenylmethylamine amide, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: ethers-buliding-blocks

Referemce:
Ether – Wikipedia,
Ether | (C2H5)2O – PubChem